RankingsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. EBITDA

LIGAND PHARMACEUTICALS INC【LGND】

Market cap
$3.9B
P/E ratio
SummaryFinancials
Period EndEBITDA (Million USD)YoY (%)
Dec 31, 202413-73.93%
Dec 31, 202348-11.19%
Dec 31, 202255-58.01%
Dec 31, 2021130+152.18%
Dec 31, 202052-93.76%
Dec 31, 2019825+362.57%
Dec 31, 2018178+123.64%
Dec 31, 201780+44.61%
Dec 31, 201655+84.19%
Dec 31, 201530+34.43%
Dec 31, 201422+26.56%
Dec 31, 201318+433.35%
Dec 31, 20123+57.79%
Dec 31, 20112

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)